Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway

• Main Authors: Chen Shi (Author), Cong Wang (Author), Zhiwen Fu (Author), Jinmei Liu (Author), Yuanfeng Zhou (Author), Bao Cheng (Author), Cong Zhang (Author), Shijun Li (Author), Yu Zhang (Author)
• Format: Book
• Published: Elsevier, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Almonertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is highly selective for EGFR-activating mutations as well as the EGFR T790M mutation in patients with advanced non-small cell lung cancer (NSCLC). However, the development of resistance inevitably occ...